Abstract Vascular endothelial growth factor (VEGF) increases endothelial barrier permeability, an effect that may contribute to macular edema in diabetic retinopathy.
Introduction
One of the earliest known yet still enigmatic functions of vascular endothelial growth factor (VEGF) is to increase leakage of plasma components through the endothelial permeability barrier [1] . Barrier leakage due to VEGF has been demonstrated as early as 30 min after VEGF addition to endothelial cells cultured on semi-porous membranes [2, 3] . Other studies suggest a delayed effect requiring several hours [4, 5] . The latter is supported by the results of earlier studies suggest that prolonged treatment with VEGF sustains opening of fenestrae through which plasma components can diffuse [2, 6] .
The mechanism of the acute VEGF-induced increase in endothelial permeability is controversial. Some authors suggest that it is due to VEGF induction of caveoli to form vesicular vacuolar organelles that move plasma components across the cells [6] [7] [8] . Others provide data showing that VEGF activation of the VEGF receptor-2 rapidly activates a series of steps leading to internalization of VEcadherin and breakdown of the adherens junctions between endothelial cells [9, 10] . It seems likely that VEGF-induced increases in both transcytosis and paracellular transfer contribute to barrier leakiness, depending on the cell type, vascular bed (capillary or venule), and treatment conditions, such as duration of stimulation.
The short-term increases endothelial barrier permeability induced by VEGF may be due, at least in part, to generation of reactive oxygen or nitrogen species (ROS/RNS). For example, it has been shown that scavenging of endogenous superoxide (but not H 2 O 2 ) blunts VEGF-induced increases in endothelial barrier permeability [11] . The source of this superoxide is uncertain, with NADPH oxidase and uncoupled endothelial nitric oxide synthase activation as possible candidates. Although blockade of eNOS in brain [12] and retinal [7] microvascular endothelial cells, as well as in human umbilical vein endothelial cells (HUVECs) [13] , prevented barrier permeability increases due to VEGF, the opposite effect was observed in brain retinal endothelial cells [3] . Whatever the source of oxidative stress, it is clear that increasing cellular antioxidant capacity might be beneficial in decreasing VEGF-induced hyperpermeability. In this regard, we have shown that vitamin C, or ascorbic acid, prevents endothelial barrier leakage due to oxidized low density lipoprotein [14] and more recently due to thrombin [15] . Although ascorbate is considered an important cellular antioxidant, in both basal [16] and thrombin-activated cells [15] , the vitamin enhanced the function of eNOS to generate nitric oxide (NO). It is known from a previous study that ascorbate promotes NO generation by recycling the crucial eNOS co-factor tetrahydrobiopterin [17] . Subsequent activation of guanylate cyclase by NO to produce cyclic GMP resulted in increased cyclic AMP, which is known to tighten the endothelial barrier [18] [19] [20] .
If ascorbate can prevent increased endothelial barrier permeability due to thrombin, it might also do so with VEGF, either by scavenging ROS/RNS directly or by helping to prevent uncoupling of eNOS with subsequent superoxide generation. To examine whether intracellular ascorbate might modulate permeability-inducing effects of VEGF, we studied the effect of ascorbate on the permeability of HUVECs in response to VEGF, assessing possible antioxidant functions, as well as functions dependent on preservation of NO. 
Materials and methods

Cell Culture
HUVECs were supplied by ScienCell Research Laboratories (Carlsbad, CA) and cultured in their Endothelial Cell Medium (Cat. #1001), but without antioxidant supplements. As noted by the manufacturer, this medium contains 5 % (v/v) fetal bovine serum (Cat. #0025), 1 % (v/v) endothelial cell growth supplement (Cat. #1052), and penicillin/streptomycin (Cat. #0503). Cells were used between passages 3 and 10. Cells were cultured at 37°C in humidified air containing 5 % CO 2 .
Assay of ascorbate
Ascorbate was measured in cells cultured in 6-well plates following 3 rinses with Krebs-Ringer Hepes buffer (KRH) that contained 20 mM Hepes, 128 mM NaCl, 5.2 mM KCl, 1 mM NaH 2 PO 4 , 1.4 mM MgSO 4 , and 1.4 mM CaCl 2 , and at pH 7.4. The cell monolayer was then treated with 0.1 ml of 25 % (w/v) metaphosphoric acid, scraped from the plate with a rubber spatula, and the acidic lysate was partially neutralized with 0.35 ml of 0.1 M Na 2 HPO 4 containing 0.05 mM EDTA, pH 8.0. After centrifuging the cell lysate at 4°C for 1 min at 13,0009g, the supernatant was taken for assay of ascorbate in duplicate by high-performance liquid chromatography as previously described [21] . Intracellular ascorbate concentrations were calculated based on calculation of the intracellular distribution space of 3-O-methylglucose relative to the cell protein content [22] , which was taken as 3.6 ± 1.2 ll/mg protein [23] .
Assay of cellular oxidative stress
To measure intracellular ROS/RNS, confluent HUVECs in 96-well plates were rinsed free of culture medium and incubated for 30 min in KRH that contained 5 mM glucose and 20 lM 2 0 ,7 0 -dichlorofluorescein diacetate. The cells were then rinsed twice with the KRH/glucose medium, and the indicated reagents were added to wells in a total volume of 200 lL. Fluorescence of intracellular 2 0 ,7 0 -dichlorofluorescein was measured in a fluorescence microtiter plate reader (Synergy HT multimode microtiter reader, BioTek, Winooski, VT) at the start of incubation and after 120 min of incubation using excitation and emission wavelengths of 480 and 530 nm, respectively. The cells were maintained at 37°C throughout the incubation period. Preliminary studies revealed that there was a linear increase in cell fluorescence with time (results not shown), so the background cell fluorescence at time zero was subtracted from the reading at the 120 min time point for presentation.
Assay of endothelial permeability
HUVECs were cultured to confluence on polyethylene terephthalate cell culture inserts (6-well format, 0.4 micron pores at a density of 2 ± 0.2 9 10 6 pores per cm 2 , Falcon BD Biosciences, Franklin Lakes, NJ). Cells were cultured to confluence with 1.7 ml of medium in the upper well and 2.8 ml of medium in the lower well. After several days at confluence, agents were added as indicated, followed by duplicate measurements of permeability of the endothelial cell layer to [carboxyl- 14 C]inulin over 60 min at 37°C as previously described [24] , as derived from [25] . The permeability coefficient of [carboxyl- 14 C]inulin was calculated with correction for the rate of [carboxyl- 14 C]inulin transfer across filters after removal of cells by treatment with ammonium hydroxide [26] .
Data analysis
The results are shown as mean ? standard error. Statistical comparisons were made using GraphPad Prism version 6.05 for Windows (GraphPad Software, San Diego, CA). Differences between treatments were assessed by one-way ANOVA with post hoc testing using Tukey's or Dunnett's test, as appropriate.
Results
VEGF-induced endothelial permeability barrier leakiness is prevented by ascorbate
Endothelial cells cultured for 5-6 days on semi-porous filter supports formed a barrier to the passive diffusion of radioactive inulin across the matrix and cell layers, measured over 60 min at 37°C (Fig. 1) . Although not shown, this basal transfer rate was stable for several hours. Treatment of the cells in the upper chamber with 100 ng/ml VEGF for 0-120 min prior to the inulin transfer assay increased barrier leakiness at all time points (Fig. 1A) , indicating that the effect of VEGF to increase permeability becomes maximal at a time point less than 60 min, which was the limiting duration of the transfer assay. When cells were exposed to increasing concentrations of VEGF for 30 min before the inulin transfer assay, there was a progressive increase in barrier leakage, which became significant at 13 ng/ml VEGF and increased slightly further at 100 ng/ml (Fig. 1B) . To assess the effect of ascorbate on VEGF-induced increases in barrier permeability, cells were treated without (Fig. 1C, square) or with 100 ng/ml VEGF (Fig. 1C, circles) for 30 min followed by addition of increasing concentrations of ascorbate for 30 min before the inulin transfer assay. As expected, VEGF increased permeability as much as two-fold in the absence of ascorbate (Fig. 1C , compare square and circle at zero ascorbate). However, increasing amounts of ascorbate progressively tightened the endothelial barrier, with statistical significance reached at 13 lM ascorbate (Fig. 1C,  circles) . This shows that ascorbate addition to VEGFtreated cells potently inhibited barrier leakiness due to VEGF, although not to levels below the initial basal level. In other studies not shown, preloading the cells with ascorbate before VEGF treatment also blocked the increase in barrier leakiness due to VEGF.
Antioxidant role of ascorbate in preventing VEGFinduced barrier leakiness VEGF is known to generate ROS/RNS early in its time course of action and ROS/RNS can increase endothelial barrier permeability. To test this, HUVECs were treated for 120 min at 37°C with 100 ng/ml VEGF and the cellular fluorescence of 2 0 ,7 0 -dichlorofluorescin was used to measure ROS/RNS. As shown in Fig. 2A , this increased significantly by 20 % in response to VEGF and this increase was decreased by 42 % by co-treatment of the cells with 100 lM ascorbate. Indeed ascorbate decreased basal fluorescence in untreated cells by about 33 %. Further evidence favoring an increase in oxidative stress was the finding that VEGF concentrations of 50 ng/ml and greater decreased intracellular ascorbate in cells that had been treated for 30 min with 100 lM ascorbate (Fig. 2B) .
Finally, to test directly whether ascorbate can prevent endothelial barrier leak due to direct application of an oxidant, cells cultured on semi-porous filters were treated with increasing concentrations of ascorbate for 30 min, then treated for another 60 min with 250 lM H 2 O 2 , followed by the inulin transfer assay. As shown in Fig. 2C , H 2 O 2 treatment increased endothelial barrier permeability by 73 % and ascorbate prevented this leakiness, albeit at 2-to 3-fold higher concentrations than required for VEGF- induced leakiness. Together, these results suggest that at least part of the effect of VEGF could be due to increased oxidative stress and that ascorbate might inhibit the VEGF effect by functioning as an antioxidant.
Role of NO in VEGF-induced endothelial barrier leakiness
To assess whether eNOS is involved in acute VEGF-induced weakening the endothelial permeability barrier, we tested effects of L-NAME, using D-NAME as a negative control. In experiments not shown, concentrations of D-NAME of 100 lM and higher suppressed the VEGFinduced barrier leakage. To obtain selectivity for eNOS, concentrations of 60 lM L-and D-NAME were used. As seen in Fig. 3A , neither L-NAME nor D-NAME alone had a significant effect on basal endothelial permeability (compare 1st, 3rd, and 5th bars). However, L-NAME prevented the VEGF-induced increase in permeability (compare 2nd and 4th bars), whereas D-NAME had no effect (compare 2nd and 6th bars). The results with L-NAME indicate that eNOS contributes to the barrier weakening properties of VEGF.
If ascorbate inhibits the VEGF by preserving NO through recycling of tetrahydrobiopterin, then increasing the cellular concentration of tetrahydrobiopterin by treating cells with its precursor sepiapterin should have a similar effect. As shown in Fig. 3B , sepiapterin had no effect on basal permeability (compare 1st and 3rd bars), but it prevented the increase in permeability due to VEGF (compare 2nd and 4th bars).
Discussion
In this work, we found that treating HUVECs with VEGF for as short a time as 1 h increased endothelial barrier permeability and that this increase was completely prevented by loading the cells with ascorbate. Loading ascorbate concentrations were well within the physiologic human plasma range of the vitamin (12-60 lM). Treating the cells with 100 lM ascorbate for 90 min resulted in an intracellular ascorbate concentration of 2 mM, which is similar to its concentration in circulating human leukocytes [27] and the maximal intracellular ascorbate concentration in vivo [28] . The presence of this or even lower concentrations in endothelial cells would therefore likely blunt or prevent an acute increase in endothelial permeability due to VEGF observed in this and previous studies. Somewhat higher concentrations of ascorbate also blocked permeability increases due to direct treatment with H 2 O 2 , again suggesting that ascorbate could buffer ROS/RNS in vivo and that any culture studies of endothelial barrier function should include physiologic ascorbate concentrations in the culture medium.
The increase in endothelial barrier permeability induced by VEGF was associated with a modest but significant increase in ROS/RNS generation that was prevented by ascorbate loading. It was accompanied by a 25 % decrease in intracellular ascorbate over 90 min of incubation. This suggests that ascorbate is both sensitive to such stress and that its ability to block VEGF-induced ROS/RNS might contribute to its prevention of VEGF-induced increases in barrier permeability. At the concentrations measured in the current studies, ascorbate can neutralize intracellular superoxide [29] as well as its highly reactive downstream product peroxynitrite [30] . This primary antioxidant scavenging activity of ascorbate may thus account for a portion of its effect to decrease VEGF-induced increases in endothelial barrier permeability. Fig. 3 VEGF-induced increases in endothelial barrier permeability require eNOS. Panel A L-NAME prevents VEGF-induced increases in endothelial barrier permeability. Cells in culture medium on filters were treated for 30 min at 37°C with 60 lM L-or D-NAME as indicated, followed by addition of 100 ng/ml VEGF for another 30 min before assay of radiolabeled inulin permeability as described in ''Materials and methods'' section. Results are shown from 4 experiments, with bars not sharing the same small letters different at p \ 0.05. Panel B Sepiapterin inhibits VEGF-induced increases in endothelial permeability. HUVECs in culture medium on filters were treated at 37°C where indicated for 30 min with 30 lM sepiapterin, followed by 100 ng/ml VEGF. After 30 min, the radiolabeled inulin transfer assay was carried out. Results are shown from 8 experiments, with bars not sharing the same small letters different at p \ 0. 05 We also found that blockade of eNOS with L-NAME (but not D-NAME) prevented VEGF-induced increases in endothelial barrier permeability, as it did in most [12, 13, 31] , but not all [3] , previous studies. This supports the notion that the rapid increase in endothelial barrier leakage due to VEGF requires NO. Activation of eNOS by VEGF is thought to be due to VEGF-induced increases in intracellular calcium [32, 33] . However, it appears that in increasing eNOS activity, VEGF uncouples the enzyme, resulting in the increased superoxide and peroxynitrite generation.
We previously showed that the vitamin tightens the endothelial permeability barrier in both the basal [16] and thrombin-activated states [15] by preserving NO. That it may also do so with VEGF is plausible, especially since increasing tetrahydrobiopterin by providing the cells with its precursor sepiapterin also blocked acute VEGF-induced increases in barrier permeability. Thus, ascorbate could block VEGF-induced barrier opening both by scavenging ROS/RNS and by preserving NO itself.
The ability of ascorbate to prevent vascular leak due to VEGF could have clinical implications. For example, macular edema in diabetics with retinopathy is treated by injecting anti-VEGF antibodies into the vitreous humor of the eye [34] . Since ascorbate is severely depleted in the vitreous humor of diabetics with poor glycemic control [35] who are also likely to have macular edema [34] , it is possible that its repletion could help prevent or reverse macular edema due to VEGF, providing a safe and effective adjunct to more invasive therapies.
